Journal of Experimental & Clinical Cancer Research (JECCR) is the official scientific journal of the "Regina Elena" National Cancer Institute since 1986 which publishes manuscripts regarding significant advances in basic cancer research and offers a translational bridge from the laboratory to the clinic.

The most important aims are to open new roads for the understanding, prevention, diagnosis and treatment of cancer and to share the scientific results with the international scientific community.

JECCR has led its editorial activity by maintaining its partnership with the publisher BioMed Central - Springer Nature in London.

Thanks to its “open access” version, JECCR improved its performance in terms of rapid publication of the articles, better widespread all scientific results and higher visibility in the scientific community confirming its position in the 1st quartile among International Oncology Journals

Starting from 2022 JECCR has launched three new Special Issues entitled:

• The role of long non-coding and circular RNAs as potential cancer biomarkers
• Organoids as clinically relevant models to tailor precision medicine in cancer treatment;
• CRISPR-Cas9 system, the next generation in cancer therapy and target discovery

The main accomplishments achieved by JECCR in 2022 are:

• Impact Factor 12.658;
• 2,694,347 downloads;
• 2714 submissions;
• 293 published papers;

Most of submitted and published articles in the last years comes from International Oncology Institutes and Universities worldwide.

The “Journal of Experimental & Clinical Cancer Research” has reinforced its visibility in the international scientific community sharing the latest articles and collections by Social Media (LinkedIN, Twitter, Facebook). 

JECCR online website: https://jeccr.biomedcentral.com/